Bevacizumab in older patients with advanced colorectal or breast cancer

摘要: The incidence of colorectal and breast cancer is growing among the 550 million living people aged 65 or older. Bevacizumab was first anti-angiogenic agent approved for treatment advanced phase these cancers. Although older chronological age still hampers use modern treatments, there a widespread awareness that physiological (i.e. functional) ages may largely differ, seniority itself should not be stringent limit introduction anti-angiogenics. However, bevacizumab in general population questionable. There limited evidence favorable risk-to-benefit ratio, with efficacy data deriving from clinical trials selected only elderly patients rather good health. While summarizing recent advances, this review highlights specific features characterizing those who benefit most receiving bevacizumab.